10-K: Artelo Biosciences Faces Delisting Amid Financial Woes, Clinical Progress

Artelo Biosciences reported promising interim clinical trial results for its drug candidates but faces substantial doubt about its ability to continue as a going concern and a Nasdaq delisting threat due to insufficient stockholders' equity.

Summary

• Artelo Biosciences, a clinical-stage biopharmaceutical company, is focused on developing therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system.
• The company reported a net loss of $12.9 million for the year ended December 31, 2025, an increase from $9.8 million in 2024.
• Cash and cash equivalents decreased significantly to $0.6 million as of December 31, 2025, from $2.338 million in 2024, with negative working capital of $3.3 million.
• Interim results from the Phase 2a CAReS trial for ART27.13 in cancer-related anorexia showed a mean weight gain of 6.38% in the treatment group compared to a 5.42% loss in the placebo group, with a favorable safety profile.
• The Phase 1 Single Ascending Dose (SAD) study for ART26.12, intended for chemotherapy-induced peripheral neuropathy (CIPN), completed enrollment with favorable safety, tolerability, and dose-dependent linear absorption.
• ART12.11, a proprietary CBD cocrystal, is in pre-clinical development for anxiety disorders and rare diseases, with U.S. composition of matter patent protection until December 10, 2038.
• The company received a Nasdaq delisting notice in May 2025 for failing to meet the minimum stockholders' equity requirement and an additional deficiency notice in November 2025, but received an extension until March 30, 2026, to resolve the equity deficiency.
• Multiple capital raises were conducted in 2025, including private placements, at-the-market offerings, and convertible notes, generating several million dollars in net proceeds.
• A significant equity purchase agreement for up to $25 million (with an option for an additional $25 million) was entered into with Square Gate Capital Master Fund, LLC in January 2026.
• Mark E. Spring was appointed Chief Financial Officer and Treasurer in November 2025, replacing Gregory D. Gorgas in that role.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with mixed sentiment. While positive clinical data for ART27.13 and ART26.12 are encouraging for future product potential, the severe financial distress, including a going concern doubt, negative working capital, and Nasdaq delisting threat, significantly overshadows these advancements and presents critical operational risks.

Positives

• Interim Phase 2a CAReS trial results for ART27.13 demonstrated compelling increases in mean body weight of 6.38% in patients with cancer anorexia, compared to a 5.42% loss in the placebo group, with a consistent favorable safety profile.
• The Phase 1 first-in-human study for ART26.12 showed favorable safety, tolerability, and dose-dependent linear absorption, supporting its development for chemotherapy-induced peripheral neuropathy (CIPN) and other indications.
• ART12.11, a synthetic CBD cocrystal, has strong intellectual property protection with a U.S. composition of matter patent enforceable until December 10, 2038, and has shown improved pharmacokinetics and efficacy in nonclinical studies.
• The company secured an Equity Purchase Agreement in January 2026 for up to $25 million, with an option for an additional $25 million, providing a potential source of future funding.
• The annual meeting deficiency with Nasdaq was cured on January 30, 2026, and an extension was granted until March 30, 2026, to resolve the minimum shareholders' equity deficiency.

Negatives

• The company incurred a net loss of $12.9 million for the year ended December 31, 2025, an increase from $9.8 million in 2024.
• Cash and cash equivalents significantly decreased to $0.6 million as of December 31, 2025, from $2.338 million in 2024.
• Working capital was negative $3.3 million as of December 31, 2025, compared to positive $0.785 million in 2024.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• Received a Nasdaq delisting notice in May 2025 and a delist determination letter in November 2025 due to not meeting minimum stockholders' equity requirements.
• UK R&D tax credits are expected to decrease due to legislative changes and increased R&D activities in the U.S., potentially reducing cash flow from these credits.
• General and administrative expenses increased by $1.866 million to $5.981 million in 2025, while R&D expenses decreased, indicating a shift in spending or reduced R&D activity.

Risks

• The company will need to raise additional financing to support business objectives and cannot be sure it will be available on favorable terms or at all, potentially leading to adverse effects on operations or termination.
• Changes in UK R&D tax credit legislation may decrease the value of credits received and delay payments, impacting cash flow.
• Failure to comply with obligations under patent licenses with third parties (NEOMED, Stony Brook University) could result in the loss of vital license rights.
• Changes in regulatory requirements or unforeseen circumstances may impact the timing, cost, or successful completion of clinical trials.
• The company faces risks inherent to relatively new companies, including limited operating history, potential inability to commercially exploit research, and difficulties in generating sufficient revenue.
• Inability to obtain and maintain patent protection for products could allow competitors to commercialize similar products, adversely affecting commercialization and science.
• Compliance with various procedural measures, document submissions, and fee payments for patent protection is critical, and non-compliance could reduce or eliminate patent protection.
• The company may be subject to claims challenging the inventorship of its patents and other intellectual property, leading to litigation costs and potential loss of rights.
• Intellectual property rights may not address all potential threats, and litigation could cause substantial resource expenditure and distract personnel.
• The company's ability to research, develop, and commercialize product candidates is dependent on acquiring and maintaining third-party contract research facilities with controlled substance licenses.
• Product candidates, if approved, may be subject to U.S. controlled substance laws and regulations and similar foreign controls, with non-compliance or compliance costs adversely affecting operations.
• Product candidates may not achieve expected market acceptance, limiting revenue generation due to factors like regulatory approval, efficacy, safety, physician willingness, and reimbursement.
• Results of preclinical studies and earlier clinical trials are not necessarily predictive of future results, and later-stage trials may fail.
• Clinical trials for lipid-signaling modulators and cannabinoid-based product candidates are novel with limited history, posing a significant risk that trials will not result in commercially viable products.
• Changes in consumer preferences and acceptance of cannabinoid-derived products, or negative publicity, could adversely affect business.
• The company faces a highly competitive market with larger pharmaceutical and biotechnology companies having greater resources.
• Changes in healthcare legislation or regulation (e.g., Inflation Reduction Act, state pricing laws) may affect the ability to commercialize products profitably.
• High dependence on key personnel, particularly the CEO, and intense competition for skilled personnel, poses a risk to business strategy implementation.
• Difficulties in managing organizational growth, including attracting and retaining additional managerial, scientific, and administrative staff, could delay or curtail development efforts.
• Reliance on part-time consultants for critical activities poses risks if they cannot perform timely or accept full-time employment elsewhere.
• Compromised information technology systems or data, or those of third parties, could lead to business disruptions, litigation, regulatory actions, and financial losses.
• Employee or consultant misconduct, including non-compliance with regulatory standards or fraud, could result in sanctions and reputational harm.

Future Outlook

The company expects to continue incurring significant operating losses and will require substantial additional capital to fund operations, including ongoing research and development, intellectual property maintenance, and commercialization efforts. Future capital requirements are subject to various factors, including product development plans, regulatory timelines, and economic conditions. The company intends to raise capital through equity or debt offerings and licensing. The impact of the Inflation Reduction Act (IRA) on drug pricing and R&D strategies, particularly for small molecules, is a significant uncertainty that may discourage investment and alter development pathways.

Management Comments

• Management believes that the benefits of increased protection of its potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure the company outweigh the disadvantages of discouraging these proposals because negotiation could result in an improvement of their terms.
• Management believes that a more consistent and improved bioavailability profile of ART12.11 may ultimately lead to increased safety and efficacy in humans, thus making it a preferred CBD pharmaceutical composition.
• Management plans to retain rights to internally develop and commercialize products but may seek collaborations with partners in the biopharmaceutical industry when a partnering strategy serves to maximize value for stockholders.
• Management believes that as cannabinoid-derived products become more widely accepted by the medical and scientific communities and the public at large, stigma associated with cannabinoid-derived products and treatments will moderate and, as a result, consumer demand is likely to continue to grow.
• Management recognizes that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

Industry Context

StockSavvy.ai notes that Artelo Biosciences operates in a highly competitive biopharmaceutical industry characterized by rapid technological advancements and significant R&D investment. The company's focus on lipid-signaling modulation and cannabinoid-based therapies places it in an emerging but increasingly scrutinized market. The Inflation Reduction Act (IRA) poses a notable challenge, potentially disincentivizing small-molecule drug development due to earlier price negotiation eligibility compared to biologics, which could impact Artelo's funding and strategic decisions. The overturning of the Chevron doctrine also introduces regulatory uncertainty, potentially leading to increased litigation against the FDA and delays in drug approvals across the industry.

Comparison to Industry Standards

• The company competes with multinational pharmaceutical companies and specialized biotechnology companies such as Novartis International AG, Helsinn Therapeutics (U.S.), Inc., NGM Biopharmaceuticals Inc., Jazz Pharmaceuticals Inc., Skye Bioscience, Longboard Pharmaceuticals, and Pfizer Inc., many of whom have significantly greater financial resources and expertise.
• The market for cannabinoid-derived products is emerging and competitive, with only one plant-derived cannabinoid product (Epidiolex by GW Pharmaceuticals) having received FDA approval for specific epilepsy indications, setting a high bar for regulatory success in this novel area.
• The company's financial position, with a substantial net loss and negative working capital, falls significantly below the financial health typically seen in established pharmaceutical companies, highlighting its early-stage, high-risk profile.

Management Changes

Corporate Governance

Related Party Transactions

• Convertible notes issued between April 27, 2025, and May 1, 2025, included $350 thousand acquired by certain members of the board of directors, an officer, and consultants.
• On October 28, 2025, new convertible notes were issued, with $195 thousand of the aggregate principal amount ($692 thousand) going to related parties.
• A company owned by the Senior Vice President, European Operations, provided consulting services totaling $19 thousand in 2025.
• A company significantly influenced by a director of a subsidiary provided professional services totaling $79 thousand in 2025.
• A company controlled by a director of a subsidiary provided professional services totaling $84 thousand in 2025.
• As of December 31, 2025, $333 thousand was payable to directors for unpaid board compensation.

Stakeholder Impact

• Shareholders face significant dilution from multiple equity offerings and convertible debt, as well as potential stock price volatility and the risk of delisting from Nasdaq.
• Employees and consultants may experience uncertainty due to the company's 'going concern' status and reliance on external funding, potentially impacting retention and recruitment.
• Patients could benefit from the continued development of promising drug candidates for unmet medical needs like cancer-related anorexia and CIPN, but delays in funding or regulatory approval could impact availability.
• Creditors face increased risk due to the company's substantial losses, negative working capital, and 'going concern' doubt, which could affect the timely satisfaction of liabilities.
• Regulatory bodies are actively monitoring the company's compliance with listing standards and drug development regulations, with potential for further scrutiny or sanctions if issues are not resolved.

Next Steps

• Continue clinical trials for ART27.13 (CAReS Phase 2a) and ART26.12 (further phases for CIPN and other indications).
• Seek additional financing through equity or debt offerings, or licensing product candidates, to address the going concern issue and fund operations.
• Maintain compliance with Nasdaq listing requirements, particularly resolving the minimum stockholders' equity deficiency by March 30, 2026.
• Expand the size and capabilities of the organization by attracting and retaining additional managerial, operational, scientific, and medical personnel.
• Monitor and adapt to changes in regulatory requirements and healthcare legislation, such as the Inflation Reduction Act, which may impact drug pricing and development strategies.

Key Dates

Recommendation

Despite promising interim clinical data for ART27.13 and ART26.12, the company's severe financial distress, including a 'going concern' qualification from its auditor, negative working capital, and an ongoing Nasdaq delisting threat, presents an extremely high level of risk. The significant net losses and rapid cash burn indicate fundamental operational challenges that overshadow any clinical progress. A seasoned investor would prioritize the immediate and critical financial instability, recommending a 'sell' to mitigate exposure to potential insolvency or further significant share price decline.

Keywords

Biopharmaceutical, Clinical stage, Cancer anorexia, Chemotherapy-induced peripheral neuropathy, CIPN, Endocannabinoid system, ECS, FABP5 inhibitor, CBD cocrystal, ART27.13, ART26.12, ART12.11, Nasdaq, SEC filing, 10-K, Drug development, Lipid signaling, Going concern, Capital raise, Clinical trials